PTC Therapeutics (PTCT) Earnings: Q3 2026 Results

The quarter ended September 30, 2026 and PTC Therapeutics published the results on October 29, 2026. Revenue and diluted EPS are shown against Q3 2025, the same quarter a year earlier, which takes seasonal swings out of the comparison.

• Q3 2026 GAAP results include $111.0 million of acquired in-process research and development expense for the ST-920 Fabry disease gene therapy bought from Sangamo Therapeutics, and a $19.3 million loss on extinguishment of debt from converting the remaining 2026 Convertible Notes.
• PTC sold 100% of its Evrysdi royalty rights to Royalty Pharma, so royalty revenue is recognized against a liability for the sale of future royalties and is non-cash.

Source: PTC Therapeutics Q3 2026 results, October 29, 2026. Also in the Form 10-Q for the quarter ended September 30, 2026. Figures as reported; checked against the release on November 10, 2026.

How PTC Therapeutics splits revenue in its own release, under its own labels, for Q3 2026 against Q3 2025. Indented lines are parts of the line above them.

• PTC Therapeutics's Net product revenue revenue was $276 million in Q3 2026, up 111% from $131 million in Q3 2025, 77% of total revenue.
• PTC Therapeutics's Royalty revenue revenue was $81.7 million in Q3 2026, up 15% from $70.8 million in Q3 2025, 23% of total revenue.
• PTC Therapeutics's Collaboration and license revenue revenue was $0.2 million in Q3 2026, down 98% from $9.3 million in Q3 2025, under 1% of total revenue.

Segment lines are the figures writers cite most often, because they show where the growth in a quarter came from. Companies redraw their segments from time to time and restate the prior year to match, so a year-ago figure here can differ from the one printed a year ago. When that has happened, the note above says so.

From the earnings release

In its Q3 2026 release, PTC Therapeutics said:

“Expected total revenue increased to $1.29 to $1.32 billion, with total product revenue guidance raised to $960 to $990 million from $850 to $950 million”

“GAAP R&D and SG&A expense guidance remains $775 to $815 million”

“Non-GAAP R&D and SG&A expense guidance remains $680 to $720 million, excluding estimated non-cash, stock-based compensation expense of $95 million”

Source: PTC Therapeutics Q3 2026 release, Oct 29, 2026.

This is the company's own guidance as of Oct 29, 2026, quoted as given. Walnut does not make forecasts of its own. Analyst estimates for the coming quarters are on the PTCT forecast page.

Revenue and diluted EPS for the last 5 quarters. Each date links to that quarter's release.

GAAP total revenue and diluted EPS, each as first reported in that quarter's release. PTC's quarterly revenue swings with collaboration and license revenue, which was $998.4 million in the first nine months of 2025 and $51.0 million in the first nine months of 2026.

We do not hold a confirmed date for PTC Therapeutics's next report. Companies post the date on their investor relations site a few weeks ahead, usually with the time of the conference call.

Each quarter keeps its own page with the figures as reported, so a link to one stays pointed at the same numbers after the next report.

• Q3 2026 (this page), reported Oct 29, 2026

PTC Therapeutics had total revenue of $357.8 million in Q3 2026, against $211.0 million a year earlier. Net product revenue was $275.9 million, royalty revenue $81.7 million and collaboration and license revenue $0.2 million. (PTC Therapeutics Q3 2026 release, Oct 29, 2026; PTC Therapeutics Form 10-Q, Q3 2026, Oct 29, 2026)

Sephience, PTC's treatment for phenylketonuria (PKU), was $181.9 million of the $275.9 million in product revenue: $144.8 million in the United States and $37.1 million internationally, up 20% from Q2 2026. The FDA approved it in July 2025, so the year-ago quarter had only $19.6 million. PTC reported over 2,000 active patients worldwide as of September 30, 2026. (PTC Therapeutics Q3 2026 release, Oct 29, 2026; PTC Therapeutics Form 10-Q, Q3 2026, Oct 29, 2026; PTC Therapeutics Form 10-K, 2025, Feb 19, 2026)

PTC's older Duchenne muscular dystrophy products are shrinking. Emflaza fell to $25.1 million from $35.2 million, which PTC attributes to additional generic competition, and Translarna fell to $48.5 million from $50.7 million after the European Commission adopted the CHMP's negative opinion. Translarna's Q3 2026 revenue includes a government purchase order from Russia. (PTC Therapeutics Q3 2026 release, Oct 29, 2026; PTC Therapeutics Form 10-Q, Q3 2026, Oct 29, 2026)

By geography, US net product revenue was $173.8 million, Russia $33.0 million, Brazil $1.6 million and all other countries $67.4 million. Three distributors each accounted for over 10% of PTC's net product sales in the quarter. (PTC Therapeutics Form 10-Q, Q3 2026, Oct 29, 2026)

Royalty revenue of $81.7 million, up 15%, comes from Roche's sales of Evrysdi, which Roche reported at approximately CHF 1,470 million year to date. PTC has sold 100% of those royalty rights to Royalty Pharma, which has provided $2.1 billion of funding, so the royalty revenue does not bring in cash. Collaboration and license revenue fell 98% to $0.2 million, all for work performed for Novartis. (PTC Therapeutics Q3 2026 release, Oct 29, 2026; PTC Therapeutics Form 10-Q, Q3 2026, Oct 29, 2026)

PTC Therapeutics reported a GAAP net loss of $51.7 million, or $0.62 per diluted share, in Q3 2026, against net income of $15.9 million, or $0.20 per share, a year earlier. PTC does not report an adjusted EPS figure; its non-GAAP measures cover only R&D and SG&A expense excluding stock-based compensation. (PTC Therapeutics Q3 2026 release, Oct 29, 2026)

Two items drove the loss. PTC paid $111.0 million upfront for the ST-920 gene therapy from Sangamo Therapeutics and expensed it as acquired in-process research and development, with up to $100.0 million more in milestone payments tied to US approvals. It also recorded a $19.3 million loss on extinguishment of debt when the remaining $55.5 million of 2026 Convertible Notes converted. Interest expense, net rose 41% to $45.9 million, mostly from the royalty sale liability and the 2031 Convertible Notes. (PTC Therapeutics Q3 2026 release, Oct 29, 2026; PTC Therapeutics Form 10-Q, Q3 2026, Oct 29, 2026)

Income tax expense was $10.6 million, against a benefit of $39.0 million a year earlier, which PTC tied to recognizing revenue under the A&R Royalty Purchase Agreement. Diluted weighted average shares were 83,476,100, against 87,115,369 a year earlier; in a loss quarter dilutive securities are excluded. (PTC Therapeutics Form 10-Q, Q3 2026, Oct 29, 2026; PTC Therapeutics Q3 2026 release, Oct 29, 2026)

Diluted EPS divides net income by the weighted average number of shares outstanding in the quarter, plus the shares that options and other equity awards could add. Buybacks shrink that count and lift EPS for the same profit; share issuance and stock awards enlarge it.

PTC Therapeutics gives a full-year outlook in its release. With Q3 2026 results it raised expected 2026 total revenue to $1.29 to $1.32 billion and total product revenue guidance to $960 to $990 million, from $850 to $950 million. (PTC Therapeutics Q3 2026 release, Oct 29, 2026)

Expense guidance did not change: GAAP R&D and SG&A expense of $775 to $815 million, and non-GAAP R&D and SG&A expense of $680 to $720 million, excluding estimated stock-based compensation of $95 million. PTC said it is on track to reach cash flow breakeven this year, and expects to complete the ST-920 BLA submission in Q4 2026. (PTC Therapeutics Q3 2026 release, Oct 29, 2026)

A consensus figure is the average of the models published by the analysts who cover PTC Therapeutics, collected by a data provider and revised up to the day of the report. A quarter that lands above it says how expectations were set as much as how the business did, and the share price on the day also reflects the guidance and the lines no consensus covers.

The consensus figures on this page are Yahoo Finance's, as pulled on the date shown. Each comes with the number of analysts behind it; the smaller that number, the more one revised estimate can move the average.

The figures below are the ones PTC Therapeutics's own release and filings put weight on for Q3 2026, with the latest reported value for each.

What the quarter means for a holding is a separate question from what it reported. The case for and against owning PTCT is on is PTCT a buy or a sell?, what analysts expect next is on the PTCT forecast, and what the company does is on the PTC Therapeutics (PTCT) stock page.

Every number on this page can be traced to a document PTC Therapeutics published. Checking one takes a couple of minutes, and it is worth doing before you quote a figure anywhere.

• The results release is the document linked in the source line above. Companies publish it on their investor relations site at the moment results go out, and it carries the headline tables: revenue, operating income, net income and EPS for the quarter and the year-ago quarter.
• The same release is filed with the SEC as Exhibit 99.1 to a Form 8-K under Item 2.02, usually on the day of the report. The SEC copy does not change after the fact, which makes it the safer thing to link when you cite a number.
• The quarterly report (Form 10-Q) follows within a few weeks and carries the full financial statements, the segment note and management's discussion of what changed. The fourth quarter is covered by the annual report (Form 10-K) instead.
• Restated comparisons are flagged in the notes on this page. When a company redraws its segments or changes how it adjusts EPS, it restates the year-ago column, so the year-ago figure in a new release can differ from the one printed a year ago. This page always uses the comparison in the newer release, because that is the like-for-like one.

A walk-through of every line in a release, with what each one tells you, is in how to read an earnings report.